Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies

NCT02434809 | Active Not Recruiting FDA Drug FDA Device

• 1 other identifier: 14-225
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 3

Brief Summary

The first purpose of this study is to test a new computer program that reduces the blurring in the cone-beam CT scan and helps the doctor to better locate the tumor. The investigators want to find out what effects, good and/or bad, that this has on the patient and the way we treat the cancer in the lungs. The second purpose of this study is to test how well this computer program tracks markers in the images, compared to using radio signals to follow the markers.

Conditions

Lung Cancer

Keywords

Respiratory Motion-Corrected Cone-Beam CT; Radiation; 14-225

Outcome Measures

Primary Outcomes (1)

• successful Calypso transponder implantation

  The RapidTrack algorithm will be considered successful if the centroid position of the Calypso transponders, as determined by the RapidTrack algorithm, are within 2 mm of the positions determined by the Calypso system 95% of the time.

  1 year

Study Arms (1)

Patients with lung cancer

EXPERIMENTAL

Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6, 9, 12, 15, 18, 21 and 24 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.

Procedure: Bronchoscopic Implantation; Device: Cone-Beam CT-Guided; Radiation: stereotactic body radiation treatments

Interventions

Bronchoscopic Implantation PROCEDURE

Calypso transponders

Patients with lung cancer

Cone-Beam CT-Guided DEVICE

Patients with lung cancer

stereotactic body radiation treatments RADIATION

Patients with lung cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologic proof of malignancy suitable for thoracic radiation therapy
• Patient is planning to undergo radiation therapy for primary or recurrent malignancies of the lung or metastatic malignancies to the lung.
• Age ≥ 18 years old
• Karnofsky Performance Status ≥ 60%
• At least part of the tumor must be visible as observed in a diagnostic or planning CT.
• Able to have bronchoscopic placement of Calypso transponders as confirmed on a recent (within the past 8 weeks) CT scan.

You may not qualify if:

• Patients with clinically significant active infections.
• Bronchiectasis in the region of the intended implantation.
• History of hypersensitivity to nickel.
• Other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study.
• Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines
• Unable to tolerate anesthesia or sedation
• Enrolled in any other clinical studies the investigator believes to be in conflict with this investigation.
• Female patients who are pregnant or nursing
• Implants in the chest region that contain metal or conductive materials (e.g., metal implants, rods, or plates) which Calypso Medical considers will interfere with the Calypso System's electromagnetic localization.
• Active implanted devices, such as pacemakers, defibrillators, and drug infusion pumps since the effects of the Calypso System operation on these devices are unknown.
• Patients whose lung tumors are being monitored by MR imaging as part of standard clinical care. Implantation of transponders will degrade MR images.
• Posterior lesions that would be \>19 cm distance from Calypso detector plate.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead

Study Sites (3)

Memorial Sloan Kettering Cancer Commack

Commack, New York, 11725, United States

Location

Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Zhang Peng, PhD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 30, 2015
• First Posted: May 5, 2015
• Study Start: April 1, 2015
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): April 1, 2027
• Last Updated: May 6, 2026

Record last verified: 2026-05

Locations

US (3)